Anti-herpes simplex virus (HSV) activities of
oxyresveratrol in vitro and
topical administration in cutaneous HSV-1
infection in mice were examined. The inhibitory concentrations for 50% plaque formation (IC(50)) of
oxyresveratrol against HSV-1 clinical isolates and HSV-2 clinical isolates were 20.9-29.5 and 22.2-27.5 μg/ml, respectively. In
topical administration in cutaneous HSV-1
infection in mice, 2.5%, 5%, 10% and 20%
oxyresveratrol in cream vehicle applied three times daily for 7 days after
infection were evaluated and 10% and 20%
oxyresveratrol cream were significantly effective in delaying the development of skin lesions and protection from death (P < 0.01). The concentration of 10%
oxyresveratrol in cream was significantly more effective than that of 30%
oxyresveratrol in
vaseline applied three times daily (P < 0.01).
Oxyresveratrol cream at 20% was as effective as 5% ACV cream applied three times daily (P < 0.01). Both 10% and 20%
oxyresveratrol cream were as effective as that of 5% ACV cream applied two times daily (P > 0.05). Therapeutic efficacy of
oxyresveratrol in cream vehicle was dose-dependent and the maximum efficacy observed on day 6 after
infection was shown
at 10%
oxyresveratrol in cream applied three times daily. The frequency of application of 10%
oxyresveratrol cream at three, four and five times daily was as effective as that of 5% ACV cream applied five times daily (P > 0.05). These results demonstrated that
topical administration of
oxyresveratrol in novel cream vehicle reduced the concentration of
oxyresveratrol to 10% and was suitable for cutaneous HSV
infection.